Prevalence and screening costs of hepatitis C virus among Ugandan blood donors

Tropical Medicine and International Health

Volumn 11, Issue 6, 2006, Pages 951-954

  Hladik, W ^a,d   Kataaha, P ^b   Mermin, J ^a   Purdy, M ^a   Otekat, G ^b   Lackritz, E ^c   Alter, M J ^a   Downing, R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Department of Molecular Genetics   (Uganda)

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^d CDC Uganda   (Uganda)

Author keywords

Blood donors; Costs; Hepatitis C; Screening; Uganda

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G;

ANTIBODY; BLOOD; COST; DISEASE PREVALENCE; HEPATITIS; VIRUS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD BANK; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH CARE COST; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOBLOTTING; MALE; PREVALENCE; SCREENING TEST; SEX DIFFERENCE; SYPHILIS; UGANDA;

ADULT; ANTIBODIES, VIRAL; BLOOD DONORS; COST-BENEFIT ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HIV SEROPOSITIVITY; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; MALE; MASS SCREENING; PREVALENCE; RECOMBINANT PROTEINS; UGANDA;

AFRICA; EAST AFRICA; SUB-SAHARAN AFRICA; UGANDA;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33744937945     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2006.01643.x     Document Type: Article

References (10)

1. Alter HJ Seeff LB 2000 Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Seminars in Liver Disease 20, 17 35.
2. Alter HJ Purcell RH Shih JW et al. 1989 Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. New England Journal of Medicine 321, 1494 1500.
3. Alter MJ Kuhnert WL Finelli L 2003 Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR. Recommendations and Reports 52 RR-3 1 13, 15 quiz CE1-4.
4. Ampofo W Nii-Trebi N Ansah J et al. 2002 Prevalence of blood-borne infectious diseases in blood donors in Ghana. Journal of Clinical Microbiology 40, 3523 3525.
5. Esteban JI Gonzalez A Hernandez JM et al. 1990 Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. New England Journal of Medicine 323, 1107 1112.
6. Etard JF Colbachini P Dromigny JA Perrier-Gros-Claude JD 2003 Hepatitis C antibodies among blood donors, Senegal, 2001. Emerging Infectious Disease 9, 1492 1493.
7. Fang CT Field SP Busch MP Heyns Adu P 2003 Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing. Vox Sanguinis 85, 9 19.
8. Global Surveillance and Control of Hepatitis C 1999 Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. Journal of Viral Hepatitis 6, 35 47.
9. Schreiber GB 1996 The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study (see comments). New England Journal of Medicine 334, 1685 1690.
10. Tess BH Levin A Brubaker G et al. 2000 Seroprevalence of hepatitis C virus in the general population of northwest Tanzania. American Journal of Tropical Medicine and Hygiene 62, 138 141.